Publication:
Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsYalcin, S.; Uslu, R.; Dane, F.; Yilmaz, U.; Zengin, N.; Buyukunal, E.; Buyukberber, S.; Camci, C.; Sencan, O.; Kilickap, S.
dc.date.accessioned2022-03-10T17:50:50Z
dc.date.accessioned2026-01-11T10:52:27Z
dc.date.available2022-03-10T17:50:50Z
dc.date.issued2011
dc.identifier.doi10.1200/jco.2011.29.15_suppl.3579
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/221404
dc.identifier.wosWOS:000208880300353
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleBevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.issue15
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume29

Files

Collections

Araştırma Çıktıları